SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

SG Americas Securities LLC reduced its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 77.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,945 shares of the company’s stock after selling 80,254 shares during the quarter. SG Americas Securities LLC’s holdings in Nurix Therapeutics were worth $516,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP raised its stake in Nurix Therapeutics by 41.6% in the fourth quarter. Wellington Management Group LLP now owns 205,324 shares of the company’s stock valued at $2,119,000 after purchasing an additional 60,271 shares in the last quarter. J.W. Cole Advisors Inc. bought a new stake in shares of Nurix Therapeutics during the 1st quarter worth $265,000. Mirae Asset Global Investments Co. Ltd. grew its position in Nurix Therapeutics by 27.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,904 shares of the company’s stock worth $454,000 after acquiring an additional 6,628 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Nurix Therapeutics by 75.6% in the first quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company’s stock valued at $787,000 after acquiring an additional 23,044 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares in the last quarter.

Nurix Therapeutics Stock Down 1.2 %

NASDAQ:NRIX opened at $24.87 on Wednesday. The firm’s fifty day simple moving average is $23.44 and its 200 day simple moving average is $19.42. The stock has a market cap of $1.22 billion, a P/E ratio of -8.52 and a beta of 2.22. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the subject of a number of research reports. JPMorgan Chase & Co. upped their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. HC Wainwright boosted their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, June 18th. Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. Barclays boosted their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research report on Monday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.71.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,408 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $70,443.36. Following the transaction, the insider now directly owns 45,150 shares of the company’s stock, valued at approximately $933,250.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,105 shares of company stock valued at $1,507,181. 7.20% of the stock is currently owned by company insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.